Logout Login Cart iconShop
Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "futcoin fc 26 Besuche die Website Buyfc26coins.com. Kein Stress, super..8Yet"

Looking for quality documents?
external link icon
Repligen to Present at the 25th Annual Piper Jaffray Healthcare Conference
WALTHAM, Mass., Nov. 26, 2013 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will present an overview of the Company at the 25 th Annual Piper Jaffray Healthcare Conference on Tuesday, December 3 at 9:50 a.m. EST. The conference will be held December 3-4, 2013 at the New York Palace Hotel in New York. A live audio webcast of the Repligen presentation will be accessible through the Investor Relations section of Company's website at www.repligen.com ; see News & Events, Events & Presentations. This webcast will also be archived for a period of time on the Company's website. About Repligen Corporation Repligen Corporation is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies
external link icon
Ecolab Life Sciences and Repligen Announce the Commercial Launch of DurA Cycle Affinity Resin for Large-Scale Biologic Manufacturing
Ecolab today announced that its Purolite resin business, together with Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of Purolite’s DurA Cycle, a protein A chromatography resin for large-scale purification processes. This new affinity resin is being introduced at the BIO International Convention (BIO 2024), being held June 3-6 in San Diego. This latest innovation marks a significant milestone in Purolite’s long-term strategic partnership with Repligen, further solidifying Ecolab’s dedication to driving advancements in the bioprocessing industry. DurA Cycle is designed for large-scale commercial manufacturing of monoclonal antibodies, where cost of goods is critical for biologic drug developers. This new resin represents the latest addition to Purolite's toolbox, following two new resins launched in the last eighteen months to address purification challenges associated with
external link icon
Repligen to Participate in 13th Annual Craig-Hallum Institutional Investor Conference
WALTHAM, Mass., May 26, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a leading innovator and provider of high-value products to improve the process of manufacturing biologic drugs, today announced that it will participate in the 13 th Annual Craig-Hallum Institutional Investor Conference being held on June 1 in Minneapolis, MN. This conference provides institutional investors the opportunity to meet with Company management and does not include a formal presentation. Repligen’s most recent investor presentation will be accessible through the Investor Events section of Company’s website.
About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a life sciences company focused on the development and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are the leading manufacturer of Protein A
event icon
BIO
San Diego Convention Center | Booth #5601
external link icon
Repligen Corporation to Present at 42nd Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Dec. 19, 2023 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at the 42 nd Annual J.P. Morgan Healthcare conference being held January 8-11 in San Francisco. Tony J. Hunt, Chief Executive Officer, will present an overview of the company on Tuesday, January 9, 2024, at 2:15 p.m. PST. A live webcast of the presentation will be accessible through Repligen’s  Investor Relations website at www.repligen.com , and will be available for replay for a limited period of time following the event. About Repligen Corporation
Repligen Corporation is a life sciences tools and technology company that develops and markets highly innovative bioprocessing solutions and systems. Our products enable efficiencies in the process of manufacturing a wide range of biological drugs, including: monoclonal antibodies; recombinant proteins; cell and gene therapies; and
external link icon
Repligen To Host Investor Day 2022
WALTHAM, Mass., Aug. 24, 2022 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a leading innovator of bioprocessing technologies and solutions, today announced that it will host “Repligen Investor Day 2022” on Tuesday, September 20. The live event will take place at the Nasdaq MarketSite in New York City from 8:20 to 11:30 a.m. EDT. The event will feature presentations by several members of the company’s leadership team and will include Q&A discussion between the audience and Repligen panel members. A live webcast of “Repligen Investor Day 2022” will be accessible through the Investor Relations website at www.repligen.com and will be available for replay for a limited period of time following the event. In-person event registration is limited to institutional investors and analysts, while webcast registration is available to all. About Repligen Corporation
Repligen Corporation is a global company that develops and commercializes highly innovative bioprocessing
external link icon
Repligen to Present at Stephens Inc. Fall Investment Conference
WALTHAM, Mass., Nov. 5, 2014 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will present at the Stephens Fall Investment Conference on Wednesday, November 12 at 10:00 a.m. EST. The conference will be held at the New York Palace Hotel in New York City. An audio-only webcast of Dr. Herlihy's remarks and discussion with the audience will be accessible at the time of the presentation through the Investor Events section of Company's website. A replay of this webcast will also be accessible for a period of time following the event. About Repligen Corporation Repligen Corporation (Nasdaq:RGEN) is a life sciences company focused on the development and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are the leading manufacturer of Protein A
external link icon
Repligen CEO to Present at Upcoming Investor Conferences
- Stephens Fall Investment Conference & Piper Jaffray Healthcare Conference - Repligen Corporation (NASDAQ:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will be presenting at two investor conferences in November. Dr. Herlihy will first participate in the Stephens Fall Investment Conference on November 14, and will later present at the Piper Jaffray 24 th Annual Healthcare Conference on November 27. Both conferences will take place at The New York Palace Hotel. At each, Dr. Herlihy will provide a corporate update and address questions from the audience. Repligen’s presentation at the Piper Jaffray Annual Healthcare Conference will be webcast and made available live through the Investors section of Company’s website at www.repligen.com . This presentation is currently scheduled to begin on Tuesday, November 27 at 8:50 a.m. EST. To access the live webcast, please log on approximately 15 minutes prior to the scheduled start time. The
external link icon
Repligen to Present at Jefferies 2015 Healthcare Conference
WALTHAM, Mass., May 26, 2015 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced its upcoming presentation at the Jefferies 2015 Healthcare Conference to be held June 1-4, 2015  at the Grand Hyatt in New York. Tony J. Hunt, Repligen President and Chief Executive Officer, will present a Company overview on Wednesday, June 3, at 8:00 a.m. EDT.  A live audio webcast of this discussion will be accessible through the Investor Events section of the Company’s website. A replay of the webcast will also be accessible for a period of time following the event. About Repligen Corporation Repligen Corporation (Nasdaq:RGEN) is a life sciences company focused on the development and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are the leading manufacturer of Protein A affinity ligands, a critical component of
external link icon
Repligen Reports Second Quarter 2019 Financial Results and Updates Full Year 2019 Financial Guidance
Reports record quarterly revenue of $70.7 million, representing 48% year-over-year growth and 46% organic growth Raises revenue guidance to $264-$268 million for full year 2019, representing 29%-31% organic growth Completes acquisition of process analytics innovator C Technologies Closes follow-on equity and convertible debt offerings for net proceeds of $599 million WALTHAM, Mass., Aug. 01, 2019 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter of 2019. Provided in this press release are financial highlights for the three- and six-month periods ended June 30, 2019, updated financial guidance for the fiscal year 2019, and access information for today's webcast and conference call. Tony J. Hunt, President and Chief Executive Officer said, “We are very pleased with the company’s performance during the second quarter, which included record revenue and 46%
Close modal

A new look. A better way to explore Repligen.

We’ve redesigned Repligen.com to help you find the right solutions faster, with greater clarity and less effort.

Find what you need faster
Get to the right information with quicker site speed

Explore the site with ease
Navigate easily with an intuitive, simple site structure

Access product details instantly
Find products and resources faster, in fewer clicks

Get support when you need it
Connect with our team when you need support